After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity. 

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.

May 13, 2022
Statement
COVID-19

Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan

May 6, 2022
Statement
COVID-19

Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years

May 6, 2022
Statement
COVID-19

Novavax’ COVID-19 Vaccine Nuvaxovid™ Arrives in Singapore

Apr 29, 2022
COVID-19

FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine

Apr 22, 2022
COVID-19

Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial

Apr 20, 2022
COVID-19

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Apr 19, 2022
COVID-19

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

Apr 18, 2022
COVID-19

Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

Apr 13, 2022
COVID-19

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Apr 8, 2022
COVID-19

Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand

Highlights

Visit our global authorization website

Our commitment to equitable access and transparency

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Showper page